# MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

> **NCT02517398** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 600 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** MSB0011359C

## Key facts

- **NCT ID:** NCT02517398
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-31
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517398, "MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02517398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*